All In Biotech

Drug Trial Radar · NCT01464190

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A (NCT01324128)

Last checked: Nov 20, 2026Latest source record: Apr 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 659 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

659

Actual

Start

Sep 2011

Primary completion

Oct 2012

Study completion Apr 2013

Sponsor

Lead sponsor
Vifor PharmaIndustry
Sponsor type
Industry
Collaborators
Fresenius Medical Care North America
First posted
Nov 3, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.

Conditions

  • Chronic Kidney Disease Requiring Chronic Dialysis

Interventions

  • PA21 (2.5 g tablet containing 500 mg iron)Drug

    Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).

  • Sevelamer carbonateDrug

    Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline and Levels at Each Time Point for Serum PhosphorusTime frame: Every 4 weeks from baseline to Week 28
  2. Change From Baseline and Levels at Each Time Point for Serum CalciumTime frame: Every 4 weeks from baseline to Week 28
  3. Change From Baseline and Levels at Each Time Point for Serum Intact Parathyroid Hormone (iPTH)Time frame: Every 4 weeks from baseline to Week 28

Locations

15 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    San Antonio, Texas

  • Medizinische Abteilung Nephrologie und Dialyse

    Sankt Pölten, Austria

  • CHU Sart Tilman

    Liège, Belgium

  • Clinical Hospital Center Rijeka

    Rijeka, Croatia

  • Hospital with Polyclinic Novy Jicin

    Nový Jičín, Czechia

  • KfH Nierenzentrum Berlin-Neukoelln

    Berlin, Germany

  • Vidzemes Hospital

    Valmiera, Latvia

  • JSC "Diaverum Clinics"

    Klaipėda, Lithuania

  • Teaching Hospital no.1 of Medical University of Lodz

    Lodz, Poland

  • Dialmed Clinic SRL

    Sibiu, Romania

  • Kemerovo Regional hospital

    Kemerovo, Russia

  • Zvezdara Clinical Medical Center

    Belgrade, Serbia

  • St Augustines Hospital

    Durban, South Africa

  • Mykolayiv Regional Hospital

    Mykolayiv, Ukraine

  • Dorset County Hospital NHS Foundation Trust

    Dorset, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.